Answers are grounded in this paper and cite their sources.
Individuals with hereditary cancer syndromes who have not developed cancer, commonly referred to as previvors, face ongoing psychosocial and behavioral challenges associated with managing inherited cancer risk. Although genetic counseling provides essential education, risk assessment, and decision support, scalable approaches are needed to provide sustained psychosocial support beyond the genetic counseling encounter. This study will evaluate the efficacy of PreCharge, a 6-month personalized digital psychosocial intervention designed for previvors. The primary objective is to determine whether PreCharge improves coping self-efficacy compared with an assessment-only control condition. Secondary objectives include evaluating effects on resilience, anxiety, depressive symptoms, cancer worry, and overall well-being, as well as participant engagement and intervention acceptability. This Phase II, two-arm, parallel-group randomized controlled trial aims to enroll 574 adults with hereditary cancer syndromes from across the United States. Eligible participants will be randomly assigned 1:1 to PreCharge or an assessment-only control condition. PreCharge provides personalized support through a web-based portal, tailored text messaging, interactive activities, self-monitoring and coping tools, educational content, weekly check-ins, and just-in-time support. Assessments will be completed at baseline, 3 months, and 6 months. The primary outcome is coping self-efficacy, measured by the Cancer Behavior Inventory-Brief Version. Intervention effects will be evaluated using longitudinal mixed-effects models following the intention-to-treat principle. If effective, PreCharge could provide a scalable approach for extending personalized psychosocial support beyond the genetic counseling encounter. The study will provide evidence regarding the efficacy, acceptability, and potential implementation of a digital intervention designed to support long-term adaptation to hereditary cancer risk.
No takes yet. Share an insight, caveat, or question.
Evers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: